BTX-A can act on sensory and motor nerves, involving different neurotransmitters and neuropeptides; it can also inhibit the release of calcitonin gene-related peptide, decreasing suburothelial sensory receptors TRPV1 and P2X, controlling local inflammation, and reducing bladder sensation and pain, with good results in pain syndrome and interstitial cystitis in adult patients [2,9,10,11]. This evidence concerns the gene TRPV1 and interstitial cystitis.